Skip to main content
Erschienen in: Journal of General Internal Medicine 11/2021

28.05.2021 | Viewpoint

Rapid Access to Medications for Opioid Use Disorder

verfasst von: Robert A. Kleinman, MD, Nathaniel P. Morris, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Excerpt

Over 1.5 million people in the USA have an opioid use disorder (OUD), and opioid-involved overdoses are a major cause of death.1 Medications for opioid use disorder (MOUD) can substantially reduce morbidity and mortality associated with OUDs, yet just 18% of people with OUDs in 2019 received these medications during the prior year.1 In several situations where timely medical attention is critical, on-demand resources, such as the National Suicide Prevention Lifeline and Poison Control, are available nationwide to rapidly provide consultation or initiate treatment. Expanding readily available access to MOUD is essential, since opioid use, overdose, and other complications often occur at times and places where care is unavailable.2
Literatur
1.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health [Internet]. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020. Available from: https://www.samhsa.gov/data/ Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health [Internet]. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020. Available from: https://​www.​samhsa.​gov/​data/​
2.
Zurück zum Zitat Wenger LD, Rosenbaum M. Drug treatment on demand--not. J Psychoactive Drugs 1994;26(1):1–11.CrossRef Wenger LD, Rosenbaum M. Drug treatment on demand--not. J Psychoactive Drugs 1994;26(1):1–11.CrossRef
3.
Zurück zum Zitat Flavin L, Malowney M, Patel NA, et al. Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States. Journal of Psychiatric Practice 2020;26(1):17–22.CrossRef Flavin L, Malowney M, Patel NA, et al. Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States. Journal of Psychiatric Practice 2020;26(1):17–22.CrossRef
4.
Zurück zum Zitat Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. J Subst Abuse Treat 2019;103:1–8.CrossRef Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. J Subst Abuse Treat 2019;103:1–8.CrossRef
5.
Zurück zum Zitat Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4. Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4.
6.
Zurück zum Zitat Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. Journal of Addiction Medicine 2020;14(2):95–8. Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. Journal of Addiction Medicine 2020;14(2):95–8.
7.
Zurück zum Zitat Samuels EA, Clark SA, Wunsch C, et al. Innovation During COVID-19: Improving Addiction Treatment Access. J Addict Med 2020;14(4):e8-e9.CrossRef Samuels EA, Clark SA, Wunsch C, et al. Innovation During COVID-19: Improving Addiction Treatment Access. J Addict Med 2020;14(4):e8-e9.CrossRef
8.
Zurück zum Zitat Tofighi B, McNeely J, Walzer D, et al. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System’s Initiative to Expand Treatment Access during the COVID-19 Pandemic. J Addict Med. 2021;Online Ahead of Print. doi: 10.1097/ADM.0000000000000809 Tofighi B, McNeely J, Walzer D, et al. A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System’s Initiative to Expand Treatment Access during the COVID-19 Pandemic. J Addict Med. 2021;Online Ahead of Print. doi: 10.1097/ADM.0000000000000809
10.
Zurück zum Zitat Kleinman RA. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US. JAMA Psychiatry 2020;77(11):1163–71.CrossRef Kleinman RA. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US. JAMA Psychiatry 2020;77(11):1163–71.CrossRef
Metadaten
Titel
Rapid Access to Medications for Opioid Use Disorder
verfasst von
Robert A. Kleinman, MD
Nathaniel P. Morris, MD
Publikationsdatum
28.05.2021
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 11/2021
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06850-1

Weitere Artikel der Ausgabe 11/2021

Journal of General Internal Medicine 11/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.